Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
10 déc. 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
05 nov. 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
30 oct. 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
26 août 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
07 août 2024 02h00 HE
|
Cellectis Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
25 juil. 2024 16h30 HE
|
Cellectis Inc.
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies for...
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
12 juin 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
04 juin 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
06 mai 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
06 mai 2024 02h00 HE
|
Cellectis Inc.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca